

## 9-References

Afonina, I., Zivarts, M., Kutuyavin, I., Lukhtanov, E., Gamper, H., and Meyer, R. B. (1997). "Efficient priming of PCR with short oligonucleotides conjugated to a minor groove binder." *Nucleic Acids Res.*, 25(13), 2657-2660.

Akiyama, T., Sudo, C., Ogawara, H., Toyoshima, K., and Yamamoto, T. (1986). "The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity." *Science*, 232(4758), 1644-1646.

Ameyaw, M. M., Tayeb, M., Thornton, N., Folayan, G., Tariq, M., Mobarek, A., Evans, D. A., Ofori-Adjei, D., and McLead, H. L. (2002). "Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer." *J. Hum. Genet.*, 47(4), 172-175.

Ameyaw, M. M., Thornton, N., and McLeod, H. L. (2000). "Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk." *J. Natl. Cancer Inst.*, 92(23), 1947.

Amundadottir, L. T., and Leder, P. (1998). "Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes." *Oncogene*, 16(6), 737-746.

Andersen, T. I., Heimdal, K. R., Skrede, M., Tveit, K., Berg, K., and Borresen, A. L. (1994). "Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility." *Hum. Genet.*, 94(6), 665-670.

Anderson, L., Henderson, C., and Adachi, Y. (2001). "Phosphorylation and rapid relocalization of 53BP1 to nuclear foci upon DNA damage." *Mol. Cell Biol.*, 21(5), 1719-1729.

Antoniou, A. C., Pharoah, P. D., McMullan, G., Day, N. E., Stratton, M. R., Peto, J., Ponder, B. J., and Easton, D. F. (2002). "A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes." *Br. J. Cancer*, 86(1), 76-83.

Balmain, A., Gray, J., and Ponder, B. (2003). "The genetics and genomics of cancer." *Nat. Genet.*, 33 Suppl, 238-244.

Baxter, S. W., and Campbell, I. G. (2001). "Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk." *J. Natl. Cancer Inst.*, 93(7), 557-559.

Berg, J. W., and Hutter, R. V. (1995). "Breast cancer." *Cancer*, 75(1 Suppl), 257-269.

Berman, D. M., Wang, Y., Liu, Z., Dong, Q., Burke, L. A., Liotta, L. A., Fisher, R., and Wu, X. (2004). "A functional polymorphism in RGS6 modulates the risk of bladder cancer." *Cancer Res.*, 64(18), 6820-6826.

Bocchinfuso, W. P., and Korach, K. S. (1997). "Mammary gland development and tumorigenesis in estrogen receptor knockout mice." *J. Mammary. Gland. Biol. Neoplasia.*, 2(4), 323-334.

Botstein, D., and Risch, N. (2003). "Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease." *Nat. Genet.*, 33 Suppl, 228-237.

Botto, L. D., and Khoury, M. J. (2001). "Commentary: facing the challenge of gene-environment interaction: the two-by-four table and beyond." *Am. J. Epidemiol.*, 153(10), 1016-1020.

Boyd, N. F., Stone, J., Vogt, K. N., Connelly, B. S., Martin, L. J., and Minkin, S. (2003). "Dietary fat and breast cancer risk revisited: a meta-analysis of the published literature." *Br. J. Cancer*, 89(9), 1672-1685.

Braakhuis, B. J., Tabor, M. P., Kummer, J. A., Leemans, C. R., and Brakenhoff, R. H. (2003). "A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications." *Cancer Res.*, 63(8), 1727-1730.

Brennan, P. (2002). "Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it?" *Carcinogenesis*, 23(3), 381-387.

Brignone, G., Cusimano, R., Dardanoni, G., Gugliuzza, M., Lanzarone, F., Scibilia, V., and Dardanoni, L. (1987). "A case-control study on breast cancer risk factors in a southern European population." *Int. J. Epidemiol.*, 16(3), 356-361.

Cai, Q., Shu, X. O., Jin, F., Dai, Q., Wen, W., Cheng, J. R., Gao, Y. T., and Zheng, W. (2003). "Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai Breast Cancer Study." *Cancer Epidemiol. Biomarkers Prev.*, 12(9), 853-859.

Callahan, R. (1989). "Genetic alterations in primary breast cancer." *Breast Cancer Res. Treat.*, 13(3), 191-203.

Callahan, R. (1998). "Somatic mutations that contribute to breast cancer." *Biochem. Soc. Symp.*, 63, 211-221.

Callahan, R., Cropp, C., Sheng, Z. M., Merlo, G., Steeg, P., Liscia, D., and Lidereau, R. (1993). "Definition of regions of the human genome affected by loss of heterozygosity in primary human breast tumors." *J. Cell Biochem. Suppl*, 17G, 167-172.

Chenevix-Trench, G., Spurdle, A. B., Gatei, M., Kelly, H., Marsh, A., Chen, X., Donn, K., Cummings, M., Nyholt, D., Jenkins, M. A., (2002). "Dominant negative ATM mutations in breast cancer families." *J. Natl. Cancer Inst.*, 94(3), 205-215.

Colditz, G. A. (1997). "Hormone replacement therapy increases the risk of breast cancer." *Ann. N. Y. Acad. Sci.*, 833, 129-136.

Colson, N. J., Lea, R. A., Quinlan, S., and Griffiths, L. R. (2006). "No role for estrogen receptor 1 gene intron 1 Pvu II and exon 4 C325G polymorphisms in migraine susceptibility." *BMC. Med. Genet.*, 7, 12.

Comings, D. E., Gade-Andavolu, R., Cone, L. A., Muhleman, D., and MacMurray, J. P. (2003). "A multigene test for the risk of sporadic breast carcinoma." *Cancer*, 97(9), 2160-2170.

Conway, K., Parrish, E., Edmiston, S. N., Tolbert, D., Tse, C. K., Geradts, J., Livasy, C. A., Singh, H., Newman, B., and Millikan, R. C. (2005). "The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study." *Breast Cancer Res.*, 7(6), R871-R880.

Coughlin, S. S., and Piper, M. (1999). "Genetic polymorphisms and risk of breast cancer." *Cancer Epidemiol. Biomarkers Prev.*, 8(11), 1023-1032.

Couse, J. F., and Korach, K. S. (1999). "Estrogen receptor null mice: what have we learned and where will they lead us?" *Endocr. Rev.*, 20(3), 358-417.

Cox, D. G., Hankinson, S. E., and Hunter, D. J. (2005). "The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk." *Pharmacogenet. Genomics*, 15(7), 447-450.

Curran, J. E., Lea, R. A., Rutherford, S., Weinstein, S. R., and Griffiths, L. R. (2001). "Association of estrogen receptor and glucocorticoid receptor gene polymorphisms with sporadic breast cancer." *Int. J. Cancer*, 95(4), 271-275.

Dapic, V., Carvalho, M. A., and Monteiro, A. N. (2005). "Breast cancer susceptibility and the DNA damage response." *Cancer Control*, 12(2), 127-136.

Deng, H. W., Li, J., Li, J. L., Dowd, R., Davies, K. M., Johnson, M., Gong, G., Deng, H., and Recker, R. R. (2000). "Association of estrogen receptor-alpha genotypes with body mass index in normal healthy postmenopausal Caucasian women." *J. Clin. Endocrinol. Metab.*, 85(8), 2748-2751.

Devereux, T. R., Risinger, J. I., and Barrett, J. C. (1999). "Mutations and altered expression of the human cancer genes: what they tell us about causes." *IARC Sci. Publ.*, (146), 19-42.

Devilee, P., Cleton-Jansen, A. M., and Cornelisse, C. J. (2001). "Ever since Knudson." *Trends Genet.*, 17(10), 569-573.

Devilee, P., and Cornelisse, C. J. (1994). "Somatic genetic changes in human breast cancer." *Biochim. Biophys. Acta*, 1198(2-3), 113-130.

Di Fiore, P. P., Pierce, J. H., Fleming, T. P., Hazan, R., Ullrich, A., King, C. R., Schlessinger, J., and Aaronson, S. A. (1987). "Overexpression of the human EGF receptor

confers an EGF-dependent transformed phenotype to NIH 3T3 cells." *Cell*, 51(6), 1063-1070.

DiTullio, R. A., Jr., Mochan, T. A., Venere, M., Bartkova, J., Sehested, M., Bartek, J., and Halazonetis, T. D. (2002). "53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer." *Nat. Cell Biol.*, 4(12), 998-1002.

Duffy, M. J. (2005). "Predictive markers in breast and other cancers: a review." *Clin. Chem.*, 51(3), 494-503.

Dumont, P., Leu, J. I., Della, P. A., III, George, D. L., and Murphy, M. (2003). "The codon 72 polymorphic variants of p53 have markedly different apoptotic potential." *Nat. Genet.*, 33(3), 357-365.

Dupont, W. D., Page, D. L., Rogers, L. W., and Parl, F. F. (1989). "Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk." *Cancer*, 63(5), 948-957.

Dutrillaux, B., Gerbault-Seureau, M., and Zafrani, B. (1990). "Characterization of chromosomal anomalies in human breast cancer. A comparison of 30 paradiploid cases with few chromosome changes." *Cancer Genet. Cytogenet.*, 49(2), 203-217.

Eccles, S. A. (2001). "The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis." *J. Mammary. Gland. Biol. Neoplasia.*, 6(4), 393-406.

Ellison, R. C., Zhang, Y., McLennan, C. E., and Rothman, K. J. (2001). "Exploring the relation of alcohol consumption to risk of breast cancer." *Am. J. Epidemiol.*, 154(8), 740-747.

Fabian, C. J., and Kimler, B. F. (2005). "Selective estrogen-receptor modulators for primary prevention of breast cancer." *J. Clin. Oncol.*, 23(8), 1644-1655.

Feigelson, H. S., and Henderson, B. E. (2000). "Future possibilities in the prevention of breast cancer: role of genetic variation in breast cancer prevention." *Breast Cancer Res.*, 2(4), 277-282.

Frank, B., Hemminki, K., Bermejo, J. L., Klaes, R., Bugert, P., Wappenschmidt, B., Schmutzler, R. K., and Burwinkel, B. (2005). "TP53-binding protein variants and breast cancer risk: a case-control study." *Breast Cancer Res.*, 7(4), R502-R505.

Frank, B., Hemminki, K., Wirtenberger, M., Bermejo, J. L., Bugert, P., Klaes, R., Schmutzler, R. K., Wappenschmidt, B., Bartram, C. R., and Burwinkel, B. (2005). "The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk." *Carcinogenesis*, 26(3), 643-647.

Friedenreich, C. M. (2002). "Commentary: improving pooled analyses in epidemiology." *Int. J. Epidemiol.*, 31(1), 86-87.

Friedenreich, C. M., and Orenstein, M. R. (2002). "Physical activity and cancer prevention: etiologic evidence and biological mechanisms." *J. Nutr.*, 132(11 Suppl), 3456S-3464S.

Gaki, V., Tsopanomichalou, M., Sourvinos, G., Tsiftsis, D., and Spandidos, D. A. (2000). "Allelic loss in chromosomal region 1q21-23 in breast cancer is associated with peritumoral angiolymphatic invasion and extensive intraductal component." *Eur. J. Surg. Oncol.*, 26(5), 455-460.

Gammon, M. D., John, E. M., and Britton, J. A. (1998). "Recreational and occupational physical activities and risk of breast cancer." *J. Natl. Cancer Inst.*, 90(2), 100-117.

Gandini, S., Merzenich, H., Robertson, C., and Boyle, P. (2000). "Meta-analysis of studies on breast cancer risk and diet: the role of fruit and vegetable consumption and the intake of associated micronutrients." *Eur. J. Cancer*, 36(5), 636-646.

Graus-Porta, D., Beerli, R. R., Daly, J. M., and Hynes, N. E. (1997). "ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling." *EMBO J.*, 16(7), 1647-1655.

Habuchi, T. (2006). "Common genetic polymorphisms and prognosis of sporadic cancers: prostate cancer as a model." *Future. Oncol.*, 2(2), 233-245.

Hall, J. M., Zuppan, P. J., Anderson, L. A., Huey, B., Carter, C., and King, M. C. (1989). "Oncogenes and human breast cancer." *Am. J. Hum. Genet.*, 44(4), 577-584.

Hanahan, D., and Folkman, J. (1996). "Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis." *Cell*, 86(3), 353-364.

Harris, C. C. (1993). "p53: at the crossroads of molecular carcinogenesis and risk assessment." *Science*, 262(5142), 1980-1981.

Hauptmann, M., Sigurdson, A. J., Chatterjee, N., Rutter, J. L., Hill, D. A., Doody, M. M., and Struewing, J. P. (2003). "Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk." *J. Natl. Cancer Inst.*, 95(16), 1251-1252.

Hecht, S. S. (2002). "Tobacco smoke carcinogens and breast cancer." *Environ. Mol. Mutagen.*, 39(2-3), 119-126.

Herynk, M. H., and Fuqua, S. A. (2004). "Estrogen receptor mutations in human disease." *Endocr. Rev.*, 25(6), 869-898.



Hewitt, S. C., and Korach, K. S. (2002). "Estrogen receptors: structure, mechanisms and function." *Rev. Endocr. Metab Disord.*, 3(3), 193-200.

Hsiao, W. C., Young, K. C., Lin, S. L., and Lin, P. W. (2004). "Estrogen receptor-alpha polymorphism in a Taiwanese clinical breast cancer population: a case-control study." *Breast Cancer Res.*, 6(3), R180-R186.

Huang, W. Y., Newman, B., Millikan, R. C., Schell, M. J., Hulka, B. S., and Moorman, P. G. (2000). "Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status." *Am. J. Epidemiol.*, 151(7), 703-714.

Iwabuchi, K., Li, B., Massa, H. F., Trask, B. J., Date, T., and Fields, S. (1998). "Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2." *J. Biol. Chem.*, 273(40), 26061-26068.

Iwase, H., Kobayashi, S., Iwata, H., Yamashita, T., Ito, K., Toyama, T., Hara, Y., Greenman, J., and Mathew, C. G. (1996). "[Molecular analysis of the estrogen receptor (ER) gene in association with ER negativity in breast cancer]." *Gan To Kagaku Ryoho*, 23 Suppl 1, 61-65.

Johnson-Thompson, M. C., and Guthrie, J. (2000). "Ongoing research to identify environmental risk factors in breast carcinoma." *Cancer*, 88(5 Suppl), 1224-1229.

Kamali-Sarvestani, E., Talei, A. R., and Merat, A. (2004). "Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women." *Cancer Lett.*, 215(1), 83-87.

Kang, D. (2003). "Genetic polymorphisms and cancer susceptibility of breast cancer in Korean women." *J. Biochem. Mol. Biol.*, 36(1), 28-34.

Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B. J., Seger, R., Hynes, N. E., and Yarden, Y. (1996). "ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer." *EMBO J.*, 15(2), 254-264.

Kelsey, J. L., and Bernstein, L. (1996). "Epidemiology and prevention of breast cancer." *Annu. Rev. Public Health*, 17, 47-67.

Kelsey, J. L., Gammon, M. D., and John, E. M. (1993). "Reproductive factors and breast cancer." *Epidemiol. Rev.*, 15(1), 36-47.

Key, T. J., Appleby, P. N., Reeves, G. K., Roddam, A., Dorgan, J. F., Longcope, C., Stanczyk, F. Z., Stephenson, H. E., (2003). "Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women." *J. Natl. Cancer Inst.*, 95(16), 1218-1226.

Khan, S. A., Rogers, M. A., Khurana, K. K., Meguid, M. M., and Numann, P. J. (1998). "Estrogen receptor expression in benign breast epithelium and breast cancer risk." *J. Natl. Cancer Inst.*, 90(1), 37-42.

Kinzler, K. W., and Vogelstein, B. (1998). "Landscaping the cancer terrain." *Science*, 280(5366), 1036-1037.

Kinzler, K. W., and Vogelstein, B. (1997). "Cancer-susceptibility genes. Gatekeepers and caretakers." *Nature*, 386(6627), 761, 763.

Knudson, A. G., Jr. (1971). "Mutation and cancer: statistical study of retinoblastoma." *Proc. Natl. Acad. Sci. U. S. A.*, 68(4), 820-823.

Knudson, A. G. (2001). "Two genetic hits (more or less) to cancer." *Nat. Rev. Cancer*, 1(2), 157-162.

Kollias, J., Man, S., Marafie, M., Carpenter, K., Pinder, S., Ellis, I. O., Blamey, R. W., Cross, G., and Brook, J. D. (2000). "Loss of heterozygosity in bilateral breast cancer." *Breast Cancer Res. Treat.*, 64(3), 241-251.

Kukita, Y., Tahira, T., Sommer, S. S., and Hayashi, K. (1997). "SSCP analysis of long DNA fragments in low pH gel." *Hum. Mutat.*, 10(5), 400-407.

Laferriere, J., Houle, F., and Huot, J. (2002). "Regulation of the metastatic process by E-selectin and stress-activated protein kinase-2/p38." *Ann. N. Y. Acad. Sci.*, 973, 562-572.

Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K. (2001). "Initial sequencing and analysis of the human genome." *Nature*, 409(6822), 860-921.

Larson, P. S., Schlechter, B. L., de las, M. A., Garber, J. E., Cupples, L. A., and Rosenberg, C. L. (2005). "Allele imbalance, or loss of heterozygosity, in normal breast epithelium of sporadic breast cancer cases and BRCA1 gene mutation carriers is increased compared with reduction mammoplasty tissues." *J. Clin. Oncol.*, 23(34), 8613-8619.

li-Osman, F., Akande, O., Antoun, G., Mao, J. X., and Buolamwini, J. (1997). "Molecular cloning, characterization, and expression in *Escherichia coli* of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins." *J. Biol. Chem.*, 272(15), 10004-10012.

Liao, L., Kuang, S. Q., Yuan, Y., Gonzalez, S. M., O'Malley, B. W., and Xu, J. (2002). "Molecular structure and biological function of the cancer-amplified nuclear receptor coactivator SRC-3/AIB1." *J. Steroid Biochem. Mol. Biol.*, 83(1-5), 3-14.

Liaw, D., Marsh, D. J., Li, J., Dahia, P. L., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacocke, M., Eng, C., and Parsons, R. (1997). "Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome." *Nat. Genet.*, 16(1), 64-67.

Lichtenstein, P., and Annas, P. (2000). "Heritability and prevalence of specific fears and phobias in childhood." *J. Child Psychol. Psychiatry*, 41(7), 927-937.

Lichtenstein, P., Holm, N. V., Verkasalo, P. K., Iliadou, A., Kaprio, J., Koskenvuo, M., Pukkala, E., Skytthe, A., and Hemminki, K. (2000). "Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland." *N. Engl. J. Med.*, 343(2), 78-85.

Liu, A., Davis, R. J., Flores, C., Menon, M., and Seethalakshmi, L. (1992). "Epidermal growth factor: receptor binding and effects on the sex accessory organs of sexually mature male mice." *J. Urol.*, 148(2 Pt 1), 427-431.

Livak, K. J., and Schmittgen, T. D. (2001). "Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method." *Methods*, 25(4), 402-408.

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M. (2004). "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib." *N. Engl. J. Med.*, 350(21), 2129-2139.

Ma, H., Hu, Z., Zhai, X., Wang, S., Wang, X., Qin, J., Chen, W., Jin, G., Liu, J., Gao, J., Wang, X., Wei, Q., and Shen, H. (2006). "Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population." *Carcinogenesis*, 27(4), 766-771.

MacLean, C. H., Newberry, S. J., Mojica, W. A., Khanna, P., Issa, A. M., Suttorp, M. J., Lim, Y. W., Traina, S. B., Hilton, L., Garland, R., and Morton, S. C. (2006). "Effects of omega-3 fatty acids on cancer risk: a systematic review." *JAMA*, 295(4), 403-415.

Maguire, P., Margolin, S., Skoglund, J., Sun, X. F., Gustafsson, J. A., Borresen-Dale, A. L., and Lindblom, A. (2005). "Estrogen receptor beta (ESR2) polymorphisms in familial and sporadic breast cancer." *Breast Cancer Res. Treat.*, 94(2), 145-152.

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Jr., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., and . (1990). "Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms." *Science*, 250(4985), 1233-1238.

Matsuzaki, H., Loi, H., Dong, S., Tsai, Y. Y., Fang, J., Law, J., Di, X., Liu, W. M., et al. (2004). "Parallel genotyping of over 10,000 SNPs using a one-primer assay on a high-density oligonucleotide array." *Genome Res.*, 14(3), 414-425.

Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., et al. (1994). "A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1." *Science*, 266(5182), 66-71.

Mitra, N., Ye, T. Z., Smith, A., Chuai, S., Kirchhoff, T., Peterlongo, P., Nafa, K., Phillips, M. S., et al. (2004). "Localization of cancer susceptibility genes by genome-wide

single-nucleotide polymorphism linkage-disequilibrium mapping." *Cancer Res.*, 64(21), 8116-8125.

Montgomery, K. G., Gertig, D. M., Baxter, S. W., Milne, R. L., Dite, G. S., McCredie, M. R., Giles, G. G., Southey, M. C., et al. (2003). "The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years." *Cancer Epidemiol. Biomarkers Prev.*, 12(10), 1109-1111.

Morales, J. C., Xia, Z., Lu, T., Aldrich, M. B., Wang, B., Rosales, C., Kellems, R. E., Hittelman, W. N., et al. (2003). "Role for the BRCA1 C-terminal repeats (BRCT) protein 53BP1 in maintaining genomic stability." *J. Biol. Chem.*, 278(17), 14971-14977.

Mueller, S. O., and Korach, K. S. (2001). "Estrogen receptors and endocrine diseases: lessons from estrogen receptor knockout mice." *Curr. Opin. Pharmacol.*, 1(6), 613-619.

Nathanson, K. L., Wooster, R., and Weber, B. L. (2001). "Breast cancer genetics: what we know and what we need." *Nat. Med.*, 7(5), 552-556.

Negrini, M., Sabbioni, S., Possati, L., Rattan, S., Corallini, A., Barbanti-Brodano, G., and Croce, C. M. (1994). "Suppression of tumorigenicity of breast cancer cells by microcell-mediated chromosome transfer: studies on chromosomes 6 and 11." *Cancer Res.*, 54(5), 1331-1336.

Nelson, S. E., Gould, M. N., Hampton, J. M., and Trentham-Dietz, A. (2005). "A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer." *Breast Cancer Res.*, 7(3), R357-R364.

Newcomb, P. A. (1997). "Lactation and breast cancer risk." *J. Mammary. Gland. Biol. Neoplasia.*, 2(3), 311-318.

Niu, G., and Carter, W. B. (2007). "Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways." *Cancer Res.*, 67(4), 1487-1493.

Noviello, C., Courjal, F., and Theillet, C. (1996). "Loss of heterozygosity on the long arm of chromosome 6 in breast cancer: possibly four regions of deletion." *Clin. Cancer Res.*, 2(9), 1601-1606.

Oldenburg, R. A., Kroeze-Jansema, K., Kraan, J., Morreau, H., Klijn, J. G., Hoogerbrugge, N., Ligtenberg, M. J., van Asperen, C. J., (2003). "The CHEK2\*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families." *Cancer Res.*, 63(23), 8153-8157.

Oldenburg, R. A., Kroeze-Jansema, K., Kraan, J., Morreau, H., Klijn, J. G., Hoogerbrugge, N., Ligtenberg, M. J., van Asperen, C. J. (2003). "The CHEK2\*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families." *Cancer Res.*, 63(23), 8153-8157.

Onay, V. U., Briollais, L., Knight, J. A., Shi, E., Wang, Y., Wells, S., Li, H., Rajendram, I., Andrulis, I. L., and Ozcelik, H. (2006). "SNP-SNP interactions in breast cancer susceptibility." *BMC. Cancer*, 6, 114.

Orita, M., Iwahana, H., Kanazawa, H., Hayashi, K., and Sekiya, T. (1989). "Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms." *Proc. Natl. Acad. Sci. U. S. A*, 86(8), 2766-2770.

Papewalis, J., Nikitin, A. Y., and Rajewsky, M. F. (1991). "G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene." *Nucleic Acids Res.*, 19(19), 5452.

Parkin, D. M., Bray, F., Ferlay, J., and Pisani, P. (2005). "Global cancer statistics, 2002." *CA Cancer J. Clin.*, 55(2), 74-108.

Payne, S. R., and Kemp, C. J. (2005). "Tumor suppressor genetics." *Carcinogenesis*, 26(12), 2031-2045.

Persson, I. (2000). "Estrogens in the causation of breast, endometrial and ovarian cancers - evidence and hypotheses from epidemiological findings." *J. Steroid Biochem. Mol. Biol.*, 74(5), 357-364.

Pharoah, P. D., Antoniou, A., Bobrow, M., Zimmern, R. L., Easton, D. F., and Ponder, B. A. (2002). "Polygenic susceptibility to breast cancer and implications for prevention." *Nat. Genet.*, 31(1), 33-36.

Pharoah, P. D., and Ponder, B. A. (2002). "The genetics of ovarian cancer." *Best. Pract. Res. Clin. Obstet. Gynaecol.*, 16(4), 449-468.

Ramaswamy, S. V., Reich, R., Dou, S. J., Jasperse, L., Pan, X., Wanger, A., Quitugua, T., and Graviss, E. A. (2003). "Single nucleotide polymorphisms in genes associated with isoniazid resistance in *Mycobacterium tuberculosis*." *Antimicrob. Agents Chemother.*, 47(4), 1241-1250.

Ramaswamy, S. V., Reich, R., Dou, S. J., Jasperse, L., Pan, X., Wanger, A., Quitugua, T., and Graviss, E. A. (2003). "Single nucleotide polymorphisms in genes associated with isoniazid resistance in *Mycobacterium tuberculosis*." *Antimicrob. Agents Chemother.*, 47(4), 1241-1250.



Rapakko, K., Heikkinen, K., Karppinen, S. M., Erkkö, H., and Winqvist, R. (2007). "Germline alterations in the 53BP1 gene in breast and ovarian cancer families." *Cancer Lett.*, 245(1-2), 337-340.

Richer, J., and Chudley, A. E. (2005). "The hemoglobinopathies and malaria." *Clin. Genet.*, 68(4), 332-336.

Risch, N. J. (2000). "Searching for genetic determinants in the new millennium." *Nature*, 405(6788), 847-856.

Roodi, N., Bailey, L. R., Kao, W. Y., Verrier, C. S., Yee, C. J., Dupont, W. D., and Parl, F. F. (1995). "Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer." *J. Natl. Cancer Inst.*, 87(6), 446-451.

Rosen, E. M., Fan, S., Pestell, R. G., and Goldberg, I. D. (2003). "BRCA1 gene in breast cancer." *J. Cell Physiol*, 196(1), 19-41.

Russo, J., and Russo, I. H. (1999). "Cellular basis of breast cancer susceptibility." *Oncol. Res.*, 11(4), 169-178.

Rutter, J. L., Chatterjee, N., Wacholder, S., and Struwing, J. (2003). "The HER2 I655V polymorphism and breast cancer risk in Ashkenazim." *Epidemiology*, 14(6), 694-700.

Sakamuro, D., Sabbatini, P., White, E., and Prendergast, G. C. (1997). "The polyproline region of p53 is required to activate apoptosis but not growth arrest." *Oncogene*, 15(8), 887-898.

Schmidt, L., Duh, F. M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., et al. (1997). "Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas." *Nat. Genet.*, 16(1), 68-73.

Shearman, A. M., Cooper, J. A., Kotwinski, P. J., Humphries, S. E., Mendelsohn, M. E., Housman, D. E., and Miller, G. J. (2005). "Estrogen receptor alpha gene variation and the risk of stroke." *Stroke*, 36(10), 2281-2282.

Shin, A., Kang, D., Nishio, H., Lee, M. J., Park, S. K., Kim, S. U., Noh, D. Y., Choe, K. J., et al. (2003). "Estrogen receptor alpha gene polymorphisms and breast cancer risk." *Breast Cancer Res. Treat.*, 80(1), 127-131.

Sjoblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., et al. (2006). "The consensus coding sequences of human breast and colorectal cancers." *Science*, 314(5797), 268-274.

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. (1987). "Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene." *Science*, 235(4785), 177-182.

Smith, G., Stanley, L. A., Sim, E., Strange, R. C., and Wolf, C. R. (1995). "Metabolic polymorphisms and cancer susceptibility." *Cancer Surv.*, 25, 27-65.

Smith-Warner, S. A., Spiegelman, D., Yaun, S. S., Adami, H. O., Beeson, W. L., van den Brandt, P. A., Folsom, A. R. (2001). "Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies." *JAMA*, 285(6), 769-776.

Sommer, S., and Fuqua, S. A. (2001). "Estrogen receptor and breast cancer." *Semin. Cancer Biol.*, 11(5), 339-352.

Stern, D. F. (2000). "Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases." *Breast Cancer Res.*, 2(3), 176-183.

Stern, D. F., Heffernan, P. A., and Weinberg, R. A. (1986). "p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity." *Mol. Cell Biol.*, 6(5), 1729-1740.

Stoll, B. A. (1998). "Western diet, early puberty, and breast cancer risk." *Breast Cancer Res. Treat.*, 49(3), 187-193.

Storey, A., Thomas, M., Kalita, A., Harwood, C., Gardiol, D., Mantovani, F., Breuer, J., Leigh, I. M., et al. (1998). "Role of a p53 polymorphism in the development of human papillomavirus-associated cancer." *Nature*, 393(6682), 229-234.

Sunnucks, P. (2000). "Efficient genetic markers for population biology." *Trends Ecol. Evol.*, 15(5), 199-203.

Takano, K., Ogasahara, K., Kaneda, H., Yamagata, Y., Fujii, S., Kanaya, E., Kikuchi, M., Oobatake, M., and Yutani, K. (1995). "Contribution of hydrophobic residues to the stability of human lysozyme: calorimetric studies and X-ray structural analysis of the five isoleucine to valine mutants." *J. Mol. Biol.*, 254(1), 62-76.

Tang, B., Bottinger, E. P., Jakowlew, S. B., Bagnall, K. M., Mariano, J., Anver, M. R., Letterio, J. J., and Wakefield, L. M. (1998). "Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency." *Nat. Med.*, 4(7), 802-807.

Tavani, A., Gallus, S., La, V. C., Negri, E., Montella, M., Dal, M. L., and Franceschi, S. (1999). "Risk factors for breast cancer in women under 40 years." *Eur. J. Cancer*, 35(9), 1361-1367.

Thor, A. D., Liu, S., Edgerton, S., Moore, D., Kasowitz, K. M., Benz, C. C., Stern, D. F., and DiGiovanna, M. P. (2000). "Activation (tyrosine phosphorylation) of ErbB-2 (HER-

2/neu): a study of incidence and correlation with outcome in breast cancer." *J. Clin. Oncol.*, 18(18), 3230-3239.

Tutt, A., and Ashworth, A. (2002). "The relationship between the roles of BRCA genes in DNA repair and cancer predisposition." *Trends Mol. Med.*, 8(12), 571-576.

Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunakaran, D., Lavi, S., Ratzkin, B. J., and Yarden, Y. (1996). "A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor." *Mol. Cell Biol.*, 16(10), 5276-5287.

Ushiroyama, T., Heishi, M., Higashio, S., Ikeda, A., and Ueki, M. (2001). "The association between postmenopausal vertebral bone mineral density and estrogen receptor gene alleles in ethnic Japanese living in western Japan." *Res. Commun. Mol. Pathol. Pharmacol.*, 109(1-2), 15-24.

Van den Brandt, P. A., Spiegelman, D., Yaun, S. S., Adami, H. O., Beeson, L., Folsom, A. R., Fraser, G., Goldbohm, R. A. (2000). "Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk." *Am. J. Epidemiol.*, 152(6), 514-527.

Vasconcelos, A., Medeiros, R., Veiga, I., Pereira, D., Carrilho, S., Palmeira, C., Azevedo, C., and Lopes, C. S. (2002). "Analysis of estrogen receptor polymorphism in codon 325 by PCR-SSCP in breast cancer: association with lymph node metastasis." *Breast J.*, 8(4), 226-229.

Venkatachalam, S., Shi, Y. P., Jones, S. N., Vogel, H., Bradley, A., Pinkel, D., and Donehower, L. A. (1998). "Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation." *EMBO J.*, 17(16), 4657-4667.

Vogelstein, B., and Kinzler, K. (2002). "The genetic basis of human cancer."

Walker, K. K., and Levine, A. J. (1996). "Identification of a novel p53 functional domain that is necessary for efficient growth suppression." *Proc. Natl. Acad. Sci. U. S. A.*, 93(26), 15335-15340.

Wang, B., Matsuoka, S., Carpenter, P. B., and Elledge, S. J. (2002). "53BP1, a mediator of the DNA damage checkpoint." *Science*, 298(5597), 1435-1438.

Wang, V. W., Bell, D. A., Berkowitz, R. S., and Mok, S. C. (2001). "Whole genome amplification and high-throughput allelotyping identified five distinct deletion regions on chromosomes 5 and 6 in microdissected early-stage ovarian tumors." *Cancer Res.*, 61(10), 4169-4174.

Wang-Gohrke, S., and Chang-Claude, J. (2001). "Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk." *J. Natl. Cancer Inst.*, 93(21), 1657-1659.

Ward, I. M., Minn, K., van, D. J., and Chen, J. (2003). "p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice." *Mol. Cell Biol.*, 23(7), 2556-2563.

Weber, B. L., and Nathanson, K. L. (2000). "Low penetrance genes associated with increased risk for breast cancer." *Eur. J. Cancer*, 36(10), 1193-1199.

Wedren, S., Lovmar, L., Humphreys, K., Magnusson, C., Melhus, H., Syvanen, A. C., Kindmark, A., Landegren, U. (2004). "Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study." *Breast Cancer Res.*, 6(4), R437-R449.

Weel, A. E., Uitterlinden, A. G., Westendorp, I. C., Burger, H., Schuit, S. C., Hofman, A., Helmerhorst, T. J., van Leeuwen, J. P., and Pols, H. A. (1999). "Estrogen receptor polymorphism predicts the onset of natural and surgical menopause." *J. Clin. Endocrinol. Metab.*, 84(9), 3146-3150.

Weiderpass, E., Persson, I., Melhus, H., Wedren, S., Kindmark, A., and Baron, J. A. (2000). "Estrogen receptor alpha gene polymorphisms and endometrial cancer risk." *Carcinogenesis*, 21(4), 623-627.

Weiss, J. R., Moysich, K. B., and Swede, H. (2005). "Epidemiology of male breast cancer." *Cancer Epidemiol. Biomarkers Prev.*, 14(1), 20-26.

Williams, R. S., Green, R., and Glover, J. N. (2001). "Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1." *Nat. Struct. Biol.*, 8(10), 838-842.

Wong, K. K., Tsang, Y. T., Shen, J., Cheng, R. S., Chang, Y. M., Man, T. K., and Lau, C. C. (2004). "Allelic imbalance analysis by high-density single-nucleotide polymorphic allele (SNP) array with whole genome amplified DNA." *Nucleic Acids Res.*, 32(9), e69.

Wooster, R., and Stratton, M. R. (1995). "Breast cancer susceptibility: a complex disease unravels." *Trends Genet.*, 11(1), 3-5.

Xie, D., Shu, X. O., Deng, Z., Wen, W. Q., Creek, K. E., Dai, Q., Gao, Y. T., Jin, F., and Zheng, W. (2000). "Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk." *J. Natl. Cancer Inst.*, 92(5), 412-417.

Xu, J., and Li, Q. (2003). "Review of the in vivo functions of the p160 steroid receptor coactivator family." *Mol. Endocrinol.*, 17(9), 1681-1692.

Yoshidome, K., Shibata, M. A., Couldrey, C., Korach, K. S., and Green, J. E. (2000). "Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptor $\alpha$  expression during tumor progression." *Cancer Res.*, 60(24), 6901-6910.

Yue, W., Santen, R. J., Wang, J. P., Li, Y., Verderame, M. F., Bocchinfuso, W. P., Korach, K. S., Devanesan, P., Todorovic, R. (2003). "Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis." *J. Steroid Biochem. Mol. Biol.*, 86(3-5), 477-486.

Yue, W., Wang, J. P., Li, Y., Bocchinfuso, W. P., Korach, K. S., Devanesan, P. D., Rogan, E., Cavalieri, E., and Santen, R. J. (2005). "Tamoxifen versus aromatase inhibitors for breast cancer prevention." *Clin. Cancer Res.*, 11(2 Pt 2), 925s-930s.

Zheng, S. L., Zheng, W., Chang, B. L., Shu, X. O., Cai, Q., Yu, H., Dai, Q., Xu, J., and Gao, Y. T. (2003). "Joint effect of estrogen receptor beta sequence variants and endogenous estrogen exposure on breast cancer risk in Chinese women." *Cancer Res.*, 63(22), 7624-7629.

Zheng, W., Gustafson, D. R., Sinha, R., Cerhan, J. R., Moore, D., Hong, C. P., Anderson, K. E., Kushi, L. H., Sellers, T. A., and Folsom, A. R. (1998). "Well-done meat intake and the risk of breast cancer." *J. Natl. Cancer Inst.*, 90(22), 1724-1729.

Zubor, P., Vojvodova, A., Danko, J., Kajo, K., Szunyogh, N., Lasabova, Z., Biringer, K., Visnovsky, J. (2006). "HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia." *Neoplasma*, 53(1), 49-55.

Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., and Dracopoli, N. C. (1996). "Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma." *Nat. Genet.*, 12(1), 97-99.

